The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan.
 
Kana Miyazaki
Honoraria - Abbvie; Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Incyte; Janssen; Meiji Seika Kaisha; Nippon Shinyaku; Novartis; SymBio Pharmaceuticals
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Ayumi Fujimoto
Honoraria - Chugai Pharma; Meiji Seika Kaisha; Sanofi
 
Senzo Taguchi
No Relationships to Disclose
 
Naoko Asano
Honoraria - Takeda
 
Wataru Munakata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Eisai; Genmab; Gilead Sciences; Janssen; Nippon Kayaku; Nippon Shinyaku; Novartis Pharmaceuticals UK Ltd.; ONO PHARMACEUTICAL; SymBio Pharmaceuticals; Takeda
Research Funding - Chugai Pharma (Inst); Genmab (Inst); Janssen (Inst); Kyowa Kirin (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Takeda (Inst)
 
Mitsuhito Hirano
No Relationships to Disclose
 
Masahiro Takeuchi
No Relationships to Disclose
 
Jun Amaki
No Relationships to Disclose
 
Jun Takizawa
Honoraria - Abbvie; AstraZeneca; Chugai Pharma; Janssen; Kyowa Kirin; Novartis; Sumitomo Dainippon Pharma
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Kyowa Kirin (Inst); Nippon Kayaku (Inst); Nippon Shinyaku (Inst); Novartis (Inst)
 
Noriko Fukuhara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; SymBio Pharmaceuticals
Research Funding - Abbvie (Inst); Chordia Therapeutics (Inst); Chugai Pharma (Inst); Genmab (Inst); Incyte (Inst); Incyte Japan (Inst); Kyowa Kirin International (Inst); Loxo/Lilly (Inst); Takeda (Inst)
 
Rika Sakai
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; CSL Behring; Eisai; Janssen; Kyowa Kirin; Meiji Seika Kaisha; Mundipharma; Nihon Medi-Physics; Nippon Shinyaku; Sanofi; SymBio Pharmaceuticals; Takeda; Towa Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Kirin (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Maeda
Honoraria - Abbvie; Asahi Kasei; Bristol-Myers Squibb; Janssen; Meiji Seika Kaisha; MSD; Nippon Shinyaku; SymBio Pharmaceuticals; Takeda
 
Toshiyuki Imagumbai
No Relationships to Disclose
 
Yuri Miyazawa
No Relationships to Disclose
 
Yoshihiro Kameoka
Honoraria - AstraZeneca; CareNet; Chugai Pharma; Eisai; Meiji Seika Kaisha; Nippon Shinyaku; Novartis; Ono Pharmaceutical; SymBio Pharmaceuticals
 
Makoto Yoshimitsu
Honoraria - Daiichi Sankyo; Novartis; Sanofi; Takeda
Consulting or Advisory Role - Takeda
 
Isao Tawara
Honoraria - Abbvie; Alexion Pharmaceuticals; Asahi Kasei; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; CSL Behring; Eisai; Janssen; Kyowa Kirin; Meiji Seika Kaisha; MSD; Novartis; Novo Nordisk; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Dainippon Pharma
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Sumitomo Dainippon Pharma (Inst); Sumitomo Dainippon Pharma (Inst); Takeda (Inst)
 
Yasuo Ejima
No Relationships to Disclose
 
Ritsuro Suzuki
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Kyowa Kirin; Meiji Seika Kaisha; MSD; Nippon Shinyaku; Novartis; Otsuka; Shionogi; Sumitomo Dainippon Pharma; Takeda
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Kyowa Kirin (Inst); Meiji Seika Kaisha (Inst); Otsuka (Inst); Shionogi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Motoko Yamaguchi
Honoraria - Abbvie; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kyowa Kirin International; Meiji Seika Kaisha; MSD; Nippon Shinyaku; SymBio Pharmaceuticals; Takeda
Research Funding - Asahi Kasei (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); Incyte (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Takeda (Inst)